MPPG

Discontinued Product

MPPG (Cat. No. 0853) has been withdrawn from sale for commercial reasons.
Description: Group III and group II mGlu antagonist; more selective for group III than group II
Chemical Name: (RS)-α-Methyl-4-phosphonophenylglycine
Datasheet
Citations (1)
Reviews
Literature (3)

Biological Activity for MPPG

MPPG is a potent antagonist of L-AP4-induced effects in rat spinal cord, thalamic and hippocampal neurons, showing selectivity over (1S,3S)-ACPD-induced effects. Potent antagonist of mGlu receptors linked to adenylyl cyclase in adult rat cortical slices.

Technical Data for MPPG

M. Wt 245.17
Formula C9H12NO5P
Storage Store at RT
CAS Number 169209-65-8
PubChem ID 3972752
InChI Key PAONCRJPUQXPRW-UHFFFAOYSA-N
Smiles NC(C(O)=O)(C)C1=CC=C(P(O)(O)=O)C=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for MPPG

Certificate of Analysis is currently unavailable on-line.
Please contact Customer Service

References for MPPG

References are publications that support the biological activity of the product.

Bedingfield et al (1996) Novel potent selective phenylglycine antagonists of metabotropic glutamate receptors. Eur.J.Pharmacol. 309 71 PMID: 8864696

Bushell et al (1996) Pharmacological antagonism of the actions of group II and group III mGluR agonists in the lateral perforant path of rat hippocampal slices. Br.J.Pharmacol. 117 1457 PMID: 8730739

Jane et al (1995) New phenylglycine derivatives with potent and selective antagonist activity at presynaptic glutamate receptors in neonatal rat spinal cord. Neuropharmacology 34 851 PMID: 8532166

Salt and Turner (1996) Antagonism of the presumed presynaptic action of L-AP4 on GABAergic transmission in the ventrobasal thalamus by the novel mGluR anatagonist MPPG. Neuropharmacology 35 239 PMID: 8734494

Keywords: MPPG, MPPG supplier, Group, III, group, II, mGlur, antagonists, selective, Receptors, mGlu4, mGlu6, mGlu7, mGlu8, mGluR4, mGluR6, mGluR7, mGluR8, Glutamate, Metabotropic, (Metabotropic), 0853, Tocris Bioscience

1 Citation for MPPG

Citations are publications that use Tocris products. Selected citations for MPPG include:

Dobson et al (2015) Caffeine Modulates Vesicle Release and Recovery at Cerebellar Parallel Fibre Terminals, Independently of Calcium and Cyclic AMP Signalling. Mol Cancer Res 10 e0125974 PMID: 25933382


Reviews for MPPG

There are currently no reviews for this product. Be the first to review MPPG and earn rewards!

Have you used MPPG?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.